Cidara Therapeutics Merger with Merck Completes; Shares to Delist

summarizeSummary

Cidara Therapeutics, Inc. announced the successful completion of its tender offer and subsequent merger with Merck, making it a wholly-owned subsidiary and leading to its delisting from Nasdaq.

check_boxKey Events

• Merger Completed

  The merger of Cidara Therapeutics, Inc. with Caymus Purchaser, Inc., a wholly-owned indirect subsidiary of Merck, officially closed on January 7, 2026. Cidara Therapeutics will continue as the surviving corporation and a wholly-owned subsidiary of Merck.

• Tender Offer Successful

  The tender offer for Cidara's common shares at $221.50 per share expired on January 6, 2026. Approximately 88.3% of the total voting shares were validly tendered and not withdrawn, satisfying the minimum condition for the acquisition.

• Delisting Imminent

  As a result of the merger, Cidara Therapeutics' common shares will be delisted from the Nasdaq Capital Market, and the company will cease to trade publicly. Merck intends to terminate the registration of the common shares and suspend all reporting obligations under the Exchange Act.

auto_awesomeAnalysis

The completion of the tender offer and subsequent merger signifies the end of Cidara Therapeutics, Inc. as an independent publicly traded company. Shareholders who tendered their shares will receive $221.50 per common share in cash. The company will now operate as a wholly-owned subsidiary of Merck, and its common shares will be delisted from the Nasdaq Capital Market, terminating all public reporting obligations. This event fundamentally alters the investment thesis for Cidara Therapeutics, as it is no longer a standalone entity.